Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTCD), a leader in the field of regenerative medicine, announced today that the US Patent and Trademark Office (USPTO) has issued U.S. patent 8,822,218 covering methods of manufacturing dendritic cells using a highly scalable processing involving a readily renewable stem cell source as the starting materials. The derivation process covered by the patent provides a means for commercial scale manufacturing of an allogeneic, off-the-shelf immunotherapy platform.
“The addition of this new patent continues to strengthen our IP position around core cell therapy components and helps protect our leading position in the regenerative medicine field,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “It is an exciting time to be here as we concentrate our efforts on developing cures for diseases and disorders of the eye and get ready to initiate phase 2 clinical trials for the treatment of Stargardt’s macular degeneration (SMD) and age-related macular degeneration (AMD).”
Because the "good doctor" has been implementing these planned sales regularly for years. His stock is compensation and taxes are due on it. The guy also has living expenses. But, most of all, a planned sale is executed six months after the plan is put in place by a third party acting as his fiduciary agent. It is irrelevant and I suspect he knows more shares will replenish his stash!!
Stick to bashing ... math is clearly not your forte! It's NOT $623,317.00!!
And, just for the record, although I assume you knew this: it is a "Planned Sale" meaning arranged ahead of time so as not to conflict with any material news/event that is known to the seller. It is handled by a third-party and is PRE-arranged! How else is the man supposed to pay Uncle Sam when his compensation is stock based?
We ALL know what a 10b5-1 Planned Sale is ...
Form 4 just filed for Dr. L!!
PLANNED sale is the operative word here!!! The guy's gotta eat, too!!
Partnering is the way to go. We're in the same sweet spot that REGN was a few short years ago!
IN SOME CASES, SMALLER biotechnology companies gain stability from key partnerships. Kaul bought another one of his top holdings, Regeneron Pharmaceuticals (REGN) in the summer of 2010, when it was trading below $40 a share, prior to the launch of its macular-degeneration treatment, Eylea. Wall Street's expectations were low—it now trades at $253—as many investors didn't understand the value of Regeneron's partnership with Paris-based health-care giant Sanofi (SAN.France). "Because that research was funded by Sanofi, it really mitigated the downside," says Kaul.
And, believe it or not ... holding a ton of ACTC awaiting TLD announcement any time now. THAT is my "pie in the sky, make me rich someday" gem! lol
Hey guys ... keep your eye on ACTCD! Just did a reverse split (had planned it but sprung it out of the blue) and announced some real high fliers in the biotech world to their Scientific Advisory Board right on the R/S's heels. Market responded very favorably! And, now we're in wait mode for uplisting and release of ITLD. Just passing it on ... not pumping!
Yeah, it's hysterical. Just like the market reaction to the announcement of our illustrious new additions to our SAB? We aren't sitting at $9 because we did a R/S ... we moved on THAT news. Keep looking in the rearview mirror ... and get left in the dust!
Really? Oh, no ... can't hold a 25% gain. Scary stuff. Top echelon doctors and mgmt. must be lying to all of us when they say they plan to uplist. I bet they didn't get the memo that they can't qualify. "Lordy, what is we gonna do"? You are a stock God ... thanks for all you do here! If it weren't for your altruistic efforts, we'd lose all our $$. Pffffffft ... tool!!
I'm sure for the institutions that can't buy til it's listed, the idea of retail getting in ahead of them wouldn't sit well with the "bigs"! ??? I'm thinking they finally have their ducks in a row and know exactly how to attack this! Buy a few on the dips ... ;-)
Nice find, deme ... mind if I share that?
“The saddest aspect of life right now is that science gathers knowledge faster than society gathers wisdom.”
― Isaac Asimov
"Better to be thought a fool than to open your mouth and remove all doubt"!!
We're up over 25% from last week! This ain't your father's ACTC(D)!! Deal with it!
As of March 27, 2014, it had 46 issued patents and 178 pending patent applications for the development of intellectual property portfolio.
I kind of thought we'd be $10 when the "D" drops off!
You might want to look into the different markets within the Nasdaq ... but, I appreciate your more subtle bashes. Trying a new tactic? Your logic about % increase needed to reach a million is tilting at windmills ... both scenarios would require perfect execution. We'll see ...
Yup, it seems like just last week that I bought a bunch at .07! Oh, wait ... it was!! ;-)
Remember this? GILD buys Pharmasset for 11B?
by minnesotafarmcountry • 3 seconds ago Remove
Oh ... and their drug was not approved at the time and they had NO revenue! Hmmmmmm ....
And, since buying it, GILD has gone on to experience the highest valued drug launch in history with their Hep C drug. I wonder if people going blind is as BIG as that?
Reuters) - Gilead Sciences Inc (GILD.O) struck a deal to buy biotechnology company Pharmasset Inc VRUS.O for about $11 billion in a huge and risky bet on the next generation of hepatitis C treatments.
Gilead, the world's largest maker of HIV drugs, will pay $137 per share for each Pharmasset share, an 89 percent premium for a company with no significant marketed products.
Pharmasset shares had already more than tripled in the past year based on the potential of its experimental hepatitis C medicines to create a new standard of care for the 180 million people worldwide infected with the serious liver disease.